GlassScriptPhysician profile
Tarek Kteleh
NPI 1932220035
$15,047.35
in general payments reported to CMS, 2019-2025
31 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,344 · 2020: $542 · 2021: $684 · 2022: $1,665 · 2023: $4,261 · 2024: $3,390 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,577 · Consulting Fee: $1,875 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,577.45 |
| Consulting Fee | $1,875.00 |
| Education | $359.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,012.96 | 2019-2025 | |
| Abbvie INC. | $1,913.13 | 2019-2025 | |
| Amgen INC. | $1,681.66 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Janssen Biotech, INC. | $1,486.11 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,234.71 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $927.52 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $892.58 | 2019-2025 | Benlysta |
| Ucb, INC. | $691.16 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $608.47 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $381.80 | 2019-2025 | Saphnelo |
| Horizon Therapeutics Plc | $305.55 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $281.24 | 2019-2025 | Orencia |
| Lilly USA, LLC | $241.04 | 2019-2025 | Taltz |
| Mallinckrodt Enterprises LLC | $200.67 | 2019 | |
| Organon LLC | $189.98 | 2022-2025 | Hadlima, Renflexis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $147.70 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.25 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $113.68 | 2019-2024 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.49 | 2019-2024 | Cyltezo, Ofev |
| Genentech USA, INC. | $87.37 | 2019-2024 | Actemra |
| Bioventus LLC | $75.97 | 2019-2022 | |
| Celgene Corporation | $69.68 | 2019 | |
| Genzyme Corporation | $55.56 | 2023 | |
| Scilex Pharmaceuticals INC. | $39.92 | 2019 | |
| Aurinia Pharma U.S., INC. | $37.88 | 2022 | |
| Merck Sharp & Dohme LLC | $33.90 | 2019 | |
| Pacira Therapeutics, INC. | $32.94 | 2019-2020 | |
| Radius Health, INC. | $25.94 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.61 | 2021 | |
| Sandoz INC. | $14.38 | 2024 | Hyrimoz |
| Medexus Pharma, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Kteleh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.